13D Filings
Allakos Inc.
Amendment
Ownership

100.00%

Total Shares

10,000

Issuer CIK

1564824

CUSIP

01671P100

Event Date

May 14, 2025

Accepted

May 19, 2025, 04:15 PM

Reporting Persons (8)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
TANG CAPITAL PARTNERS, LP
Partnership
100.00%10,000010,000
KEVIN TANG
Individual
100.00%10,000010,000
CONCENTRA BIOSCIENCES, LLC
Other
100.00%10,000010,000
TANG CAPITAL MANAGEMENT, LLC
Other
100.00%10,000010,000
CONCENTRA MERGER SUB III, INC
CO
0.00%000
TANG CAPITAL PARTNERS INTERNATIONAL, LP
Partnership
0.00%000
TANG CAPITAL PARTNERS III, INC
CO
0.00%000
TANG CAPITAL PARTNERS IV, INC
CO
0.00%000
Disclosure Items (3)

Security Title

Common Stock, par value $0.001 per share

Issuer Name

Allakos Inc.

Issuer Address

825 Industrial Road, San Carlos, CA, 94070

Item 4 of the Schedule 13D is amended by adding the following: Closing of the Merger: As previously disclosed, each of Concentra, the Issuer and Merger Sub III entered into the Merger Agreement, which provides for an Offer by Merger Sub III for all of the Issuer's Common Stock. The Offer commenced on April 15, 2025. On May 15, 2025, the Offer expired and Merger Sub III accepted for purchase a total of 73,398,243 shares tendered and not withdrawn, representing approximately 81.21% of the total shares of the Issuer issued and outstanding. Following the expiration of the Offer, Merger Sub III merged with and into the Issuer on May 15, 2025, pursuant to Section 251(h) of the Delaware General Corporation Law, and, among other things, each share of common stock of Merger Sub III issued and outstanding immediately before the Effective Time automatically converted into the right to receive the Offer Price, with the Issuer surviving as a wholly owned subsidiary of Concentra.

Percentage of Class

The information previously provided in response to Item 5 is hereby amended and restated by replacing the text thereof in its entirety with the following: The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons beneficially own an aggregate of 10,000 shares of the Issuer's Common Stock, representing 100% of the outstanding shares.

Number of Shares

See item 5(a) above.

Transactions

Except as described in this Amendment No. 3, there have been no transactions in the Issuer's Common Stock during the past 60 days by the Reporting Persons.

Shareholders

No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock beneficially owned by the Reporting Persons.

Date of 5% Ownership

Not applicable.